Sarepta Sinks On Mixed DMD Gene Therapy Study
Blames 'Bad Luck In Randomization Process'
Executive Summary
Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.
You may also be interested in...
Beam And Verve Benefit From Buzz Around Base-Editing Therapies
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.
Pfizer Planning To Start Phase III DMD Gene Therapy Trial, With Safety Monitoring Protocols
Updated Phase Ib data showed safety issues due to complement activation, but Pfizer is confident the benefits outweigh the risks and monitoring systems will help as it moves into Phase III.
RedHill Could Soon Seek EUA For COVID-19 Therapy
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports